An evidence-based analysis of FDA-approved oncology drug economics, patent strategy, and what the numbers actually mean for payers, investors, and […]

Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.

Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.

The pharmaceutical landscape is a complex tapestry woven with threads of innovation, regulation, and intricate supply chains. For strategic pharmaceutical

A Comprehensive Industry Report regarding the Technological, Economic, and Regulatory Transformation of the Pharmaceutical Sector (2025-2030) Executive Summary: The End

For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug

Deconstructing the Crisis in Pharmaceutical R&D For decades, the pharmaceutical industry has operated on a model of innovation that, while

Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition

1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into